Cover Image
Company report - 244588

Valeant Partnering 2010-2015

Published by Current Partnering, a division of Wildwood Ventures Limited
Published Content info 100 Pages
Back to Top
Valeant Partnering 2010-2015
Published: July 1, 2015 Content info: 100 Pages

This report provides all the information you require to better understand Valeant and its partnering interests and activities over the past seven years.


The Partnering Agreements with Valeant 2005-2015 report provides an in-depth insight into the partnering interests and activites of one of the worlds leading biopharma companies.

This report provides all the information you require to better understand Valeant and its partnering interests and activities over the past seven years.

On demand company reports are prepared upon purchase to ensure inclusion of the most up to date deal and company data.

The report will be delivered in PDF format within 3 working days of receipt of order. If CD-Rom version purchased, the report will be sent by courier using express service.

One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.

Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the company's business development objectives.

The initial chapters of this report provide an orientation of bigpharma's dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading partnering and M&A 2010 to present date based on headline value.

Chapter 4 provides details on how to approach bigpharma companies with partnering opportunities whilst chapter 5 lists forthcoming partnering events and conferences where bigpharma companies will be present to discuss opportunities face to face.

The main body of the report is provided in chapter 6. A profile of the company provides everything required to assess the suitability of a company as a prospective partner. This includes a company overview, partnering interests, partnering activity according to deal type, industry sector, phase of development, and therapy area. The profile also includes in-depth contact information for individuals within the business development function.

The deals are listed by deal type, stage of development and therapy focus, allowing easy access to deals and alliances of interest. Every deal record links to an online, live version of the deal record at the Current Agreements deals and alliances database. Where available, deal records also include the contract document as disclosed at the SEC.

One of the key aspects of partnering is conducting due diligence on a partner to determine under what terms a prospective partner agrees to a partnering relationship.

Understanding the flexibility of prospective partners' negotiated deals terms provides critical insight into the negotiation process in termsof what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

In addition, contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each parties ability to derive value from the deal.

In summary, the report provides the user with the tools to make successful contact with the right partners effectively and efficiently.


Partnering Agreements with Valeant report provides the user with the following key benefits:

  • Detailed company profile of the company
  • Partnering interests and therapy focus revealed
  • Partnering activity since 2010 - number of deals per year
  • Partnering activity for 2010-present
  • Activity by deal type
  • Activity by phase of development
  • Activity by therapeutic area
  • List of recent partner companies
  • Detailed listing of all partnering deals since 2010
  • Comprehensive access to actual contracts entered into by the company and its partners*
  • Insight into the terms included in a partnering agreement
  • Understand the key deal terms the company has agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies
  • Subject to being published via regulatory requirements of the Securities Exchange Commission.
Table of Contents

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Biopharma top 50 and dealmaking activity

  • 2.1 Biopharma partnering activity
  • 2.2 Biopharma M&A activity

Chapter 3 - Top bigpharma deals by value

  • 3.1 Bigpharma M&A
  • 3.2 Bigpharma partnering

Chapter 4 - Submitting Opportunities to Prospective Partners

  • 4.1 How to submit an opportunity
  • 4.2 Opportunity submission template
  • 4.3 Sending emails
  • 4.4 Face to face at partnering events
  • 4.5 Online submission forms

Chapter 5 - Forthcoming partnering events

Chapter 6 - Company Profile

  • 6.1 How to use company profiles
  • 6.2 Field definitions
  • 6.3 Company profile Partnering deals directory (2010-present) - by industry sector
  • Bigpharma
  • Pharmaceutical
  • Biotech
  • Diagnostic
  • Drug delivery
  • Government
  • Medical device
  • Consumer health
  • Specialty pharma
  • Generic pharma
  • Agricultural
  • Animal health
  • Academic
  • Non-profit
  • Research tools
  • Services
  • Partnering deals directory (2010-present) - By deal type
  • Asset purchase
  • Co-Development
  • Co-Market
  • Co-Promotion
  • Collaborative R&D
  • Contract service
  • Development
  • Distribution
  • Evaluation
  • Joint venture
  • Licensing
  • Manufacture
  • Marketing
  • Promotion
  • Research
  • Royalty financing
  • Supply
  • Partnering deals directory (2010-present) - M&A
  • Partnering deals directory (2010-present) - By stage of development
  • Discovery
  • Preclinical
  • Phase I
  • Phase II
  • Phase III
  • Regulatory
  • Marketed
  • Formulation
  • Partnering deals directory (2010-present) - By therapy area
  • Hospital care
  • Cardiovascular
  • Central nervous system
  • Cosmetic
  • Dental
  • Dermatology
  • Gastrointestinal
  • Genetic disorders
  • Genitourinary
  • Hemotology
  • Immunology
  • Infectives
  • Inflammatory
  • Metabolic
  • Musculoskeletal
  • Oncology
  • Ophthalmics
  • Respiratory
  • Sensory organ
  • About Wildwood Ventures
  • Current Partnering
  • Current Agreements
  • Recent titles from CurrentPartnering
  • Order Form - Reports
  • Order Form - Partnering Agreements
  • Company Profiles


  • Figure 1: Bigpharma partnering activity - top 50 by pharma sales
  • Figure 2: Bigpharma M&A activity - top 50 by pharma sales
  • Figure 3: Leading M&A deals involving bigpharma by value, 2010-2015
  • Figure 4: Leading partnering deals by value, 2010-2015
  • Figure 5: Typical partnering opportunity submission template
  • Figure 6: Company profile template and definitions used in report
  • Figure 7: Dealmaking frequency 2010-2015
  • Figure 8: Current partner companies (2010-present)
  • Figure 9: Partnering deals by type (2010-present)
  • Figure 10: Recent deals (2010-present) by industry sector
  • Figure 11: Recent deals (2010-present) by deal type
  • Figure 12: Recent deals (2010-present) by stage of development
  • Figure 13: Recent deals (2010-present) by therapy area
Back to Top